EpilepsyGTx, a biotechnology company focused on the research and development of gene therapies to treat focal refractory epilepsy, announced it has raised $10 million in seed funding. The funding was led by the UCL Technology Fund, with participation from Health Technology Holding.
This funding round will be used to complete the preclinical studies for EpilepsyGTx’ lead gene therapy program EPY201, and to prepare an innovative first-in-human, Phase 1/2a clinical study with EPY201 in focal refractory epilepsy.
EpilepsyGTx is a spinout company set up with the support of UCL’s commercialisation company UCL Business Ltd (UCLB).
KEY QUOTES:
“This funding is a clear vote of confidence from our investors in our vision, the world-class science of the UCL Queen Square Institute of Neurology, and the transformative potential of EPY201 in focal refractory epilepsy. Our mission is to make patients with focal refractory epilepsy seizure-free.”
- Nicolas Koebel, chief executive officer
“EpilepsyGTx has an objectively world-leading pipeline of genetic therapies for a common and damaging neurological disorder with few treatment options, developed by a globally-renowned clinical, scientific and translational team at the UCL Queen Square Institute of Neurology. We are enormously pleased to have Nicolas Koebel on board as CEO, with a track record of building exceptional global biotech companies from inception to commercial launch. We are excited that this industry-leading team now has the opportunity to translate medicines that have the potential to change the lives of patients with epilepsy and other CNS disorders.”
- Simon Goldman, Partner at AlbionVC, manager of the UCL Technology Fund and EpilepsyGTx Board member
“We have been delighted to support Nicolas and his team on their commercialization journey, and it’s terrific to see them reach this major funding milestone. We are excited by the commercial potential of this technology and its possible contribution to improve the lives of people with focal refractory epilepsy.”
- Caitriona O’Rourke, UCLB’s Business Manager for EpilepsyGTx
“We were highly impressed by the scientific strategy of the company and the credentials of the leadership team. The targeted, highly localized delivery of gene therapy is the right solution to treat focal refractory epilepsy, and is poised to make an enormous difference in the lives of millions of patients.”
- Michele Gaiotto, Managing Director at Health Technology Holding
